How does Zepbound (tirzepatide) compare to Wegovy (semaglutide)?

The Head-to-Head Comparison Everyone Wants

Dr. Christopher McGowan tackles the question that dominates every GLP-1 discussion forum online: is Zepbound (tirzepatide) better than Wegovy (semaglutide)? The answer is more nuanced than the clickbait headlines suggest, and McGowan, who specializes in obesity medicine and has prescribed both drugs extensively, is well-positioned to lay it out.

First, the basics. Wegovy is semaglutide 2.4mg weekly, made by Novo Nordisk. It is a GLP-1 receptor agonist. Zepbound is tirzepatide (5mg, 10mg, or 15mg weekly), made by Eli Lilly. It is a dual GLP-1 and GIP receptor agonist. Both are FDA-approved for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity. Both are weekly subcutaneous injections. Both are expensive.

The key molecular difference is that tirzepatide hits two receptors instead of one. GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone that, like GLP-1, is released from the gut after eating. Activating both pathways simultaneously produces stronger effects on insulin sensitivity, appetite suppression, and fat metabolism. Think of it as two radio stations playing the same song versus one. The signal is stronger.

Efficacy Data: The Numbers Tell a Clear Story

McGowan walks through the clinical trial data side by side. The STEP trials (semaglutide/Wegovy) showed average weight loss of about 15-17% of body weight at 68 weeks. The SURMOUNT trials (tirzepatide/Zepbound) showed average weight loss of about 20-22% at the highest dose (15mg) at 72 weeks. In a direct comparison, that is roughly 5 percentage points more weight loss with tirzepatide.

To put that in real numbers: a 220-pound person on Wegovy might lose about 35 pounds. The same person on Zepbound at the highest dose might lose about 45 pounds. That is a meaningful difference, about 10 pounds more on average. For patients close to surgical thresholds, those extra pounds can change the treatment calculus significantly.

The SURMOUNT-2 trial, which focused specifically on obese patients with type 2 diabetes, showed average weight loss of 14.7% with tirzepatide 15mg. The STEP-2 trial, the comparable semaglutide study in diabetic patients, showed about 9.6%. Diabetic patients typically lose less weight on GLP-1 drugs than non-diabetic patients (the reasons are not fully understood but likely involve insulin resistance and metabolic adaptation), so these lower numbers are expected. But the relative advantage of tirzepatide persisted.

HbA1c reduction was also greater with tirzepatide across studies. More patients on tirzepatide achieved HbA1c levels below 5.7% (which is technically the non-diabetic range) than on semaglutide. This has led some endocrinologists to prefer tirzepatide as first-line therapy for patients with both obesity and type 2 diabetes.

Side Effects: Similar but Not Identical

GI side effects are the primary concern with both drugs. Nausea, vomiting, diarrhea, and constipation are common during dose escalation. McGowan notes that in his clinical experience, the side effect profiles are roughly comparable between the two drugs, which aligns with the trial data. Discontinuation rates due to adverse events were similar in STEP and SURMOUNT trials.

There is a theoretical argument that tirzepatide should cause worse GI side effects because it is more potent. But GIP receptor activation may actually have a protective effect on GI tolerance, which could explain why the side effects are not proportionally worse despite the greater efficacy. This is still being studied, and individual responses vary significantly.

McGowan makes a practical point about side effect management that applies to both drugs: the slow dose titration is there for a reason. Patients who ask to skip doses or jump to higher doses faster to accelerate weight loss almost always regret it. The escalation schedule was designed to allow your GI system to adapt gradually. Respect the schedule.

Both drugs carry the same class warnings for pancreatitis, gallbladder disease, and the theoretical medullary thyroid cancer risk from animal studies. Neither has shown a statistically significant increase in thyroid cancer in human trials, but the follow-up period is still relatively short. The gallbladder risk is real and dose-dependent, higher with greater weight loss regardless of which drug is used.

Cost and Access: Where Reality Hits Theory

This is where the comparison gets frustrating. Both drugs have list prices around $1,000-$1,300 per month. Insurance coverage is inconsistent, with some plans covering one but not the other, and many plans covering neither for weight loss specifically. Medicare does not cover either drug for obesity (though congressional efforts to change this are ongoing).

McGowan has seen patients respond well to one drug and have to switch to the other purely because their insurance changed or a formulary was updated. He has also seen patients who could not access either branded drug benefit from compounded semaglutide during the FDA shortage period. The access space is frustrating for physicians and patients alike.

Manufacturer savings programs exist for both drugs. Novo Nordisk and Eli Lilly both offer cards that can reduce copays significantly for commercially insured patients. But these programs typically do not apply to government insurance, and they have annual caps. If your insurance does not cover the drug at all, the savings card may reduce the cost but still leave you paying several hundred dollars per month.

For patients paying out of pocket, cost per percentage point of weight loss is an interesting (if depressing) way to compare. If both drugs cost roughly the same and tirzepatide produces about 30% more weight loss, the per-unit value favors tirzepatide. But this calculation only matters if you can afford either drug in the first place.

Choosing Between Them: A Decision Framework

McGowan provides a practical framework for choosing. If maximum weight loss is your primary goal and cost is not a barrier, tirzepatide has the stronger data. If you have type 2 diabetes along with obesity, tirzepatide also shows an advantage in glucose control. If cardiovascular risk reduction is a major consideration, semaglutide has stronger published cardiovascular outcomes data (from the SELECT trial), though tirzepatide cardiovascular outcomes trials are ongoing and expected to report soon.

If you have tried semaglutide and it is not producing adequate results at the maintenance dose, switching to tirzepatide is a reasonable next step. The dual mechanism means patients who plateau on a single-agonist drug sometimes respond to the dual agonist. The reverse switch, tirzepatide to semaglutide, makes less mechanistic sense unless tolerability is the issue.

If insurance covers one but not the other, that typically makes the decision for you. Both drugs are effective. Getting a 15% weight loss on Wegovy is better than not being able to access a 20% weight loss on Zepbound because you cannot afford it. Do not let perfect be the enemy of good.

What to Monitor on Either Drug

McGowan recommends the same monitoring protocol regardless of which drug you take. Baseline labs should include fasting glucose, HbA1c, complete lipid panel, liver enzymes, kidney function, and a thyroid panel. Body composition via DEXA scan is ideal but not mandatory. Weight and waist circumference should be tracked at every visit.

At 3 months, repeat metabolic labs. You should see meaningful changes by this point if the drug is working. If HbA1c has not budged and weight loss is less than 5%, consider whether the dose needs to increase (if still titrating), whether adherence is an issue, or whether the drug is simply not working for you.

At 6 and 12 months, do a full reassessment. What has your total weight loss been? Has your body composition shifted favorably (fat loss with muscle preservation)? Have your metabolic markers improved? Has your quality of life changed? These questions should drive the decision about whether to continue, adjust, or change course.

McGowan is straightforward about the fact that both drugs are excellent options, and the differences, while real, are smaller than the benefits either one provides over doing nothing. The best GLP-1 drug is the one you can access, afford, tolerate, and take consistently. Everything else is optimization around the margins.

The SURMOUNT and STEP Trials by the Numbers

For anyone trying to compare these drugs directly, the trial numbers tell a clear story. The SURMOUNT-1 trial enrolled 2,539 adults without diabetes and tested tirzepatide at three doses (5mg, 10mg, 15mg) versus placebo over 72 weeks. Weight loss was 15.0%, 19.5%, and 20.9% respectively, compared to 3.1% for placebo. The STEP 1 trial enrolled 1,961 adults without diabetes and tested semaglutide 2.4mg versus placebo over 68 weeks. Weight loss was 14.9% with semaglutide versus 2.4% with placebo. The SURMOUNT-1 results were published in the New England Journal of Medicine in 2022, and the STEP 1 results in the same journal in 2021. Both trials had dropout rates around 14-17%, and intention-to-treat analyses confirmed the results held even when accounting for discontinuations.

The SURMOUNT-OSA trial, reported at the American Thoracic Society meeting in 2024, specifically tested tirzepatide in patients with moderate to severe obstructive sleep apnea. The apnea-hypopnea index dropped by 55-63% depending on dose and baseline severity, and about a third of participants no longer met diagnostic criteria for sleep apnea at the end of the trial. Wegovy does not yet have a dedicated sleep apnea trial, though improvement in sleep apnea has been documented as a secondary finding in the STEP trials. For patients whose primary driver for treatment is sleep-disordered breathing, the SURMOUNT-OSA data gives tirzepatide a distinct evidence advantage in that specific indication.